Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TaPiOCA: Thalidomide for Cardiac Amyloidosis
NCT02966522Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Oct 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in cardiac amyloidosis, sponsored by Seoul National University Hospital. Primary endpoint: Hematologic response at 1 year. Status: unknown.
02
Drugs
thalidomide
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT02966522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966522.